| |
|
Diagnostic Substances News
|
Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
1 hour, 29 minutes ago (PR Newswire)
Monogram Biosciences, Inc. today announced that scientific collaborators will present results on HERmark, the company's novel oncology assay, as a means to measure HER2 and predict response to Herceptin® in patients with metastatic breast cancer at the upcoming 44th ASCO Annual Meeting taking place in Chicago, Illinois.
|
| | |
Locate Industry by Company
|
| Market Capitalization: | 13B | | Price
/ Earnings: | NM | | Price
/ Book: | 6.3 | | Net
Profit Margin (mrq): | -22.8% | | Price
To Free Cash Flow (mrq): | -38.6 | | Return
on Equity: | 0.0% | | Total
Debt / Equity: | 0.3 | | Dividend
Yield: | 0.7% |
|